Who are the top shareholders of the Mangalam Drugs?

The top shareholders of Mangalam Drugs include Shri Jb Pharma Private Limited with 16.74%, individual investors with 44.55%, and two foreign institutional investors holding 0.47%. The highest public shareholder is Ashutosh Tapria at 1.91%, with 13.23% of promoter holdings pledged.

The top shareholders of Mangalam Drugs are primarily the promoters, with Shri Jb Pharma Private Limited holding the largest stake at 16.74%. Additionally, individual investors collectively own 44.55% of the shares. The company has two foreign institutional investors (FIIs) that hold a combined 0.47%. The highest public shareholder is Ashutosh Tapria, who owns 1.91% of the shares. It's worth noting that 13.2252% of the promoter holdings are pledged.

What does Mangalam Drugs do?

Mangalam Drugs and Organics Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 1972 and reporting net sales of 73 Cr and net profit of 0 Cr for March 2025. Key metrics include a market cap of Rs 128 Cr, P/E of 19.00, and a debt-equity ratio of 0.52.

Overview: <BR>Mangalam Drugs and Organics Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated in 1972 as Advent Pharma Pvt Ltd and underwent several name changes, becoming Mangalam Drugs and Organics Ltd in 2001 after converting to a Public Limited Company. The latest quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 73 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 128 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 19.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.52 <BR>Return on Equity: 4.69% <BR>Price to Book: 0.88<BR><BR>Contact Details: <BR>Address: 3rd Floor Rupam Building, 239 P D Mello Road Mumbai Maharashtra : 400001 <BR>Tel: 91-22-22616200/6300/8787 <BR>Email: contactus@mangalamdrugs.com <BR>Website: http://www.mangalamdrugs.com

Has Mangalam Drugs declared dividend?

Yes, Mangalam Drugs and Organics Ltd declared a 5% dividend (0.5 per share) with an ex-date of December 21, 2017. However, recent performance shows no dividend returns over various periods, with total returns fluctuating significantly.

Mangalam Drugs and Organics Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 21 Dec 17<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -32.44%, the dividend return was 0%, resulting in a total return of -32.44%.<BR><BR>For the 1-year period, the price return was -20.09%, the dividend return was 0%, leading to a total return of -20.09%.<BR><BR>Over the 2-year period, the price return was -22.72%, with a dividend return of 0%, culminating in a total return of -22.72%.<BR><BR>In the 3-year period, the price return was -46.19%, the dividend return was 0%, resulting in a total return of -46.19%.<BR><BR>For the 4-year period, the price return was -40.39%, the dividend return was 0%, leading to a total return of -40.39%.<BR><BR>In the 5-year period, the price return was 32.79%, with a dividend return of 0%, resulting in a total return of 32.79%.<BR><BR>Overall, while Mangalam Drugs declared a dividend in the past, the recent performance shows no dividend returns in the last several periods, and the total returns have varied significantly, reflecting a challenging financial landscape.

Who are the peers of the Mangalam Drugs?

Peers of Mangalam Drugs include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Parnax Lab, Source Natural, Bharat Immunolog, and Samrat Pharma. Mangalam Drugs has average management risk, below average growth, and a below average capital structure, with a 1-year return of -18.62%, significantly lower than its peers.

Peers: The peers of Mangalam Drugs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Parnax Lab, Source Natural, Bharat Immunolog, and Samrat Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Source Natural, while Good management risk is found at Divi's Lab., Torrent Pharma, and Samrat Pharma. Average management risk is present at Mangalam Drugs, and Below Average management risk is seen at Parnax Lab, Bharat Immunolog, and Ajooni Biotech. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted for Mangalam Drugs, Torrent Pharma, Bharat Immunolog, and Ajooni Biotech. Good growth is observed at Parnax Lab, and the rest have Below Average growth. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, and Parnax Lab, while Good capital structure is seen at Torrent Pharma and Source Natural. Mangalam Drugs has Below Average capital structure, and Below Average capital structure is also found at Bharat Immunolog and Ajooni Biotech.<BR><BR>Return Snapshot: Source Natural has the highest 1-year return at 105.50%, while Mangalam Drugs has the lowest at -18.62%. Compared to its peers, Mangalam Drugs' 1-year return is significantly lower. Additionally, the six-month return is negative for Mangalam Drugs, Parnax Lab, and Source Natural.

What is the technical trend for Mangalam Drugs?

As of May 22, 2025, Mangalam Drugs shows a mildly bearish trend, with daily moving averages and weekly Bollinger Bands indicating bearish signals, despite some mildly bullish indicators from MACD, KST, and OBV, while the stock has significantly underperformed the Sensex over the past year.

As of 22 May 2025, the technical trend for Mangalam Drugs has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the weekly Bollinger Bands also showing a mildly bearish signal. The MACD on a weekly basis is mildly bullish, but the monthly perspective remains bearish, suggesting mixed signals. The KST and OBV on the weekly timeframe are mildly bullish, indicating some underlying strength, yet the overall trend remains cautious. The stock's performance over the past year shows a significant decline, underperforming the Sensex, which further supports the bearish outlook.

Who are in the management team of Mangalam Drugs?

As of March 2022, the management team of Mangalam Drugs includes Govardhan M Dhoot (Chairman & Managing Director), Brijmohan Dhoot (Whole-time Director), and several independent directors: Rukmesh P. Dhandhania, Nidhi S. Mundada, and Praveen Saxena, along with Jayant Barde (Company Secretary) and Rakesh K. Milwani (Director). This team is responsible for the company's operations and governance.

As of March 2022, the management team of Mangalam Drugs includes the following individuals:<BR><BR>1. Govardhan M Dhoot - Chairman & Managing Director<BR>2. Brijmohan Dhoot - Whole-time Director<BR>3. Rukmesh P. Dhandhania - Independent Director<BR>4. Nidhi S. Mundada - Independent Director<BR>5. Praveen Saxena - Independent Director<BR>6. Jayant Barde - Company Secretary & Compliance Officer<BR>7. Rakesh K. Milwani - Director<BR><BR>This team oversees the operations and governance of the company.

How big is Mangalam Drugs?

As of 24th July, Mangalam Drugs and Organics Ltd has a market capitalization of 147.00 Cr, with recent Net Sales of 318.22 Cr and a Net Profit of 6.72 Cr. Shareholder's Funds are 135.79 Cr and Total Assets are valued at 333.70 Cr.

As of 24th July, Mangalam Drugs and Organics Ltd has a market capitalization of 147.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 318.22 Cr and a Net Profit of 6.72 Cr.<BR><BR>For the latest annual period ending March 2024, the Shareholder's Funds amounted to 135.79 Cr, while the Total Assets were valued at 333.70 Cr.

Are Mangalam Drugs latest results good or bad?

Mangalam Drugs' latest results are disappointing, with net sales down 27.9% to Rs 57.35 crore and a profit before tax of Rs -13.00 crore, marking a significant decline in profitability and operational efficiency.

The latest financial results for Mangalam Drugs and Organics indicate a challenging period for the company. For the quarter ending June 2025, net sales decreased significantly to Rs 57.35 crore, down 27.9% from the average of the previous four quarters. This decline in sales is concerning, as it reflects a downward trend in revenue generation.<BR><BR>Moreover, the profit before tax (PBT) has dropped dramatically to Rs -13.00 crore, which is a staggering decline of 1317.8% compared to the average PBT of Rs 1.07 crore in prior quarters. This is the lowest PBT the company has recorded in the last five quarters, signaling severe operational difficulties.<BR><BR>The operating profit margin has also worsened, falling to -7.79%, indicating a decline in operational efficiency. Additionally, the earnings per share (EPS) reached Rs -8.72, further highlighting the company's struggles with profitability.<BR><BR>Overall, these financial indicators suggest that Mangalam Drugs is currently facing significant challenges, and the results can be characterized as disappointing.

When is the next results date for Mangalam Drugs?

The next results date for Mangalam Drugs is 20 November 2025.

The next results date for Mangalam Drugs is scheduled for 20 November 2025.

How has been the historical performance of Mangalam Drugs?

Mangalam Drugs showed significant financial improvement from March 2024 to March 2025, with net sales decreasing to 318.23 Cr but operating profit rising to 36.33 Cr, leading to a profit after tax of 6.72 Cr. The company also experienced a strong increase in cash flow from operating activities, indicating a recovery and growth trajectory.

Answer:<BR>The historical performance of Mangalam Drugs shows a significant improvement in financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Mangalam Drugs reported net sales of 318.23 Cr, a decrease from 368.59 Cr in the previous year. Total operating income mirrored this trend, remaining at 318.23 Cr, while total expenditure excluding depreciation fell to 282.40 Cr from 351.20 Cr. This reduction in costs contributed to an operating profit (PBDIT) of 36.33 Cr, up from 17.49 Cr, reflecting a notable increase in operating profit margin from 4.73% to 11.28%. The company transitioned from a loss of 11.07 Cr in profit before tax in March 2024 to a profit of 4.79 Cr in March 2025, with profit after tax also improving from a loss of 9.07 Cr to a profit of 6.72 Cr. Earnings per share rose to 4.25 from a negative 5.73. On the balance sheet, total liabilities increased to 366.42 Cr from 333.70 Cr, while shareholder's funds grew to 148.98 Cr from 135.79 Cr. The cash flow from operating activities surged to 42.00 Cr compared to 3.00 Cr in the prior year, indicating a strong operational performance. Overall, these metrics illustrate a recovery and growth trajectory for Mangalam Drugs in the latest fiscal year.

Should I buy, sell or hold Mangalam Drugs?

Is Mangalam Drugs overvalued or undervalued?

As of November 21, 2025, Mangalam Drugs is considered a risky investment due to its negative PE ratio of -3.75, ROE of -13.07%, and an EV to EBITDA ratio of 13.75, significantly underperforming against peers like Sun Pharma and Cipla, and has a year-to-date return of -60.33% compared to the Sensex's 9.08%.

As of 21 November 2025, the valuation grade for Mangalam Drugs has moved from very attractive to risky, indicating a significant deterioration in its financial standing. The company is currently considered overvalued based on its negative PE ratio of -3.75 and a ROE of -13.07%. Additionally, the EV to EBITDA ratio stands at 13.75, which is notably higher than some peers, suggesting that investors are paying a premium despite the company's poor performance.<BR><BR>In comparison to its peers, Mangalam Drugs' valuation metrics are starkly unfavorable. For instance, Sun Pharma has a PE ratio of 36.98 and an EV to EBITDA of 24.43, while Cipla, which is rated attractive, has a PE of 22.45 and an EV to EBITDA of 15.88. The stark contrast in these ratios highlights Mangalam Drugs' overvaluation in the current market context. Furthermore, the company's stock has significantly underperformed against the Sensex, with a year-to-date return of -60.33% compared to the Sensex's 9.08%, reinforcing the notion that Mangalam Drugs is not a favorable investment at this time.

Why is Mangalam Drugs falling/rising?

As of 20-Dec, Mangalam Drugs and Organics Ltd's stock price is declining, currently at Rs 24.05, reflecting a total drop of -4.79% over the last five days. The company faces negative financial results, high debt levels, and reduced investor confidence, contributing to its ongoing stock price weakness.

As of 20-Dec, Mangalam Drugs and Organics Ltd is experiencing a decline in its stock price, currently at Rs 24.05, which reflects a change of -0.24 or -0.99%. The stock has been on a downward trend, having fallen consecutively for the last five days, resulting in a total decline of -4.79% during this period. This underperformance is further highlighted by the fact that the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a persistent weakness in price momentum.<BR><BR>The company has reported negative financial results for the last three consecutive quarters, with a significant loss of Rs -7.35 crore, which is a drastic fall of -201.2% compared to the previous four-quarter average. Additionally, the net sales have reached their lowest at Rs 49.54 crore, and the interest expenses have peaked at Rs 5.03 crore, contributing to the overall negative sentiment surrounding the stock.<BR><BR>Moreover, the company's financial health is concerning, as it has a high Debt to EBITDA ratio of 5.66 times, indicating a low ability to service its debt. The return on equity is also low at an average of 5.83%, suggesting poor profitability relative to shareholders' funds. The stock has underperformed against the benchmark indices consistently over the last three years, with a staggering -79.20% return in the past year alone.<BR><BR>Investor participation has also declined, with delivery volume dropping by -35.27% against the 5-day average, which reflects a lack of confidence among investors. Furthermore, 34.58% of promoter shares are pledged, and this proportion has increased by 21.35% over the last quarter, adding additional downward pressure on the stock price in a falling market.<BR><BR>Overall, the combination of negative operating profits, poor financial results, high debt levels, and declining investor interest are key factors contributing to the ongoing decline in Mangalam Drugs' stock price.

Which are the latest news on Mangalam Drugs?